NO20003765D0 - New sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion - Google Patents
New sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesionInfo
- Publication number
- NO20003765D0 NO20003765D0 NO20003765A NO20003765A NO20003765D0 NO 20003765 D0 NO20003765 D0 NO 20003765D0 NO 20003765 A NO20003765 A NO 20003765A NO 20003765 A NO20003765 A NO 20003765A NO 20003765 D0 NO20003765 D0 NO 20003765D0
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- cell adhesion
- bone resorption
- sulfonamide derivatives
- new sulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1248998A | 1998-01-23 | 1998-01-23 | |
| PCT/EP1999/000242 WO1999037621A1 (en) | 1998-01-23 | 1999-01-16 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003765D0 true NO20003765D0 (en) | 2000-07-21 |
| NO20003765L NO20003765L (en) | 2000-09-25 |
| NO318795B1 NO318795B1 (en) | 2005-05-09 |
Family
ID=21755208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003765A NO318795B1 (en) | 1998-01-23 | 2000-07-21 | Novel sulfonamide derivatives and pharmaceutical preparations thereof as inhibitors of bone resorption and as inhibitors of cell adhesion and processes for their preparation |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1049677A1 (en) |
| JP (1) | JP2002501054A (en) |
| KR (1) | KR20010034319A (en) |
| CN (1) | CN1177832C (en) |
| AP (1) | AP1269A (en) |
| AR (1) | AR014456A1 (en) |
| AU (1) | AU752882B2 (en) |
| BG (1) | BG104630A (en) |
| BR (1) | BR9907735A (en) |
| CA (1) | CA2318221A1 (en) |
| EA (1) | EA003102B1 (en) |
| HR (1) | HRP20000493A2 (en) |
| HU (1) | HUP0100520A3 (en) |
| ID (1) | ID26219A (en) |
| IL (1) | IL137423A0 (en) |
| NO (1) | NO318795B1 (en) |
| NZ (1) | NZ505613A (en) |
| PL (1) | PL341871A1 (en) |
| SK (1) | SK10632000A3 (en) |
| TR (1) | TR200002160T2 (en) |
| TW (1) | TWI247742B (en) |
| UA (1) | UA63990C2 (en) |
| WO (1) | WO1999037621A1 (en) |
| YU (1) | YU47200A (en) |
| ZA (1) | ZA99476B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1070707A1 (en) * | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| EP1108721A1 (en) * | 1999-12-15 | 2001-06-20 | Aventis Pharma Deutschland GmbH | Thienylalanine derivatives as inhibitors of cell adhesion |
| JP2003519119A (en) * | 1999-12-24 | 2003-06-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | (Hetero) bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives |
| FR2808798A1 (en) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease |
| FR2847254B1 (en) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM |
| JP5032299B2 (en) * | 2004-03-24 | 2012-09-26 | シャイア・オーファン・セラピーズ・ゲーエムベーハー | Novel compounds that inhibit angiogenesis and uses thereof |
| FR2870541B1 (en) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (en) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| JP6650942B2 (en) | 2014-12-17 | 2020-02-19 | ピムコ 2664 リミテッド | N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide compound and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl)- Benzenesulfonamide compounds and their therapeutic use |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2186720T3 (en) * | 1994-05-27 | 2003-05-16 | Merck & Co Inc | COMPOSITIONS TO INHIBIT OSEA-CALLAST MEDIATED OSAB REABSORPTION. |
| JP3895792B2 (en) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | Bone formation promoter |
-
1999
- 1999-01-16 AU AU25181/99A patent/AU752882B2/en not_active Ceased
- 1999-01-16 EA EA200000785A patent/EA003102B1/en not_active IP Right Cessation
- 1999-01-16 AP APAP/P/2000/001863A patent/AP1269A/en active
- 1999-01-16 PL PL99341871A patent/PL341871A1/en unknown
- 1999-01-16 SK SK1063-2000A patent/SK10632000A3/en unknown
- 1999-01-16 UA UA2000084983A patent/UA63990C2/en unknown
- 1999-01-16 ID IDW20001407A patent/ID26219A/en unknown
- 1999-01-16 WO PCT/EP1999/000242 patent/WO1999037621A1/en not_active Ceased
- 1999-01-16 TR TR2000/02160T patent/TR200002160T2/en unknown
- 1999-01-16 YU YU47200A patent/YU47200A/en unknown
- 1999-01-16 IL IL13742399A patent/IL137423A0/en unknown
- 1999-01-16 EP EP99904789A patent/EP1049677A1/en not_active Withdrawn
- 1999-01-16 CA CA002318221A patent/CA2318221A1/en not_active Abandoned
- 1999-01-16 JP JP2000528545A patent/JP2002501054A/en not_active Abandoned
- 1999-01-16 HU HU0100520A patent/HUP0100520A3/en unknown
- 1999-01-16 HR HR20000493A patent/HRP20000493A2/en not_active Application Discontinuation
- 1999-01-16 CN CNB998040894A patent/CN1177832C/en not_active Expired - Fee Related
- 1999-01-16 NZ NZ505613A patent/NZ505613A/en unknown
- 1999-01-16 KR KR1020007008041A patent/KR20010034319A/en not_active Abandoned
- 1999-01-16 BR BR9907735-3A patent/BR9907735A/en not_active IP Right Cessation
- 1999-01-22 ZA ZA9900476A patent/ZA99476B/en unknown
- 1999-01-29 AR ARP990100244A patent/AR014456A1/en not_active Application Discontinuation
- 1999-04-30 TW TW088100862A patent/TWI247742B/en active
-
2000
- 2000-07-21 BG BG104630A patent/BG104630A/en unknown
- 2000-07-21 NO NO20003765A patent/NO318795B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI247742B (en) | 2006-01-21 |
| YU47200A (en) | 2002-11-15 |
| ID26219A (en) | 2000-12-07 |
| BR9907735A (en) | 2000-10-17 |
| IL137423A0 (en) | 2001-07-24 |
| SK10632000A3 (en) | 2001-02-12 |
| CA2318221A1 (en) | 1999-07-29 |
| JP2002501054A (en) | 2002-01-15 |
| KR20010034319A (en) | 2001-04-25 |
| PL341871A1 (en) | 2001-05-07 |
| EA003102B1 (en) | 2002-12-26 |
| CN1177832C (en) | 2004-12-01 |
| AU2518199A (en) | 1999-08-09 |
| AP2000001863A0 (en) | 2000-09-30 |
| AR014456A1 (en) | 2001-02-28 |
| TR200002160T2 (en) | 2001-07-23 |
| NZ505613A (en) | 2002-11-26 |
| NO20003765L (en) | 2000-09-25 |
| NO318795B1 (en) | 2005-05-09 |
| BG104630A (en) | 2001-04-30 |
| HRP20000493A2 (en) | 2001-06-30 |
| HUP0100520A1 (en) | 2001-07-30 |
| EP1049677A1 (en) | 2000-11-08 |
| WO1999037621A1 (en) | 1999-07-29 |
| AU752882B2 (en) | 2002-10-03 |
| UA63990C2 (en) | 2004-02-16 |
| HUP0100520A3 (en) | 2002-11-28 |
| AP1269A (en) | 2004-04-03 |
| ZA99476B (en) | 1999-08-05 |
| EA200000785A1 (en) | 2001-02-26 |
| CN1293662A (en) | 2001-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20003765L (en) | New sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | |
| NO20003118D0 (en) | New acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | |
| NO973400L (en) | Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | |
| NO996313L (en) | Novel amidino derivatives and their use as thrombin inhibitors | |
| NO986180D0 (en) | Novel amidino derivatives and their use as thrombin inhibitors | |
| NO973399D0 (en) | New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | |
| DK1475377T3 (en) | Indole derivatives and their use as inhibitors of phosphodiesterase 4 | |
| NO20020635L (en) | Inhibitors of protein polymerization and the methods used | |
| NO20002958D0 (en) | Benzamidine derivatives as coagulation factor Xa inhibitors | |
| NO975740D0 (en) | Arylsulfonylaminobenzene derivatives and their use as factor Xa inhibitors | |
| DK0821671T3 (en) | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors | |
| NO20010534L (en) | Amide derivatives useful as inhibitors of cytokine production | |
| NO20030885L (en) | Inhibitors of <alfa> 4 controlled cell adhesion | |
| NO20010686D0 (en) | Hydroxypipecolate hydroxamic acid derivatives as MMP inhibitors | |
| DK0910573T3 (en) | Novel amino acid derivatives and their use as thrombin inhibitors | |
| NO20010479L (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | |
| DK1150996T3 (en) | Novel amidinobenzylamine derivatives and their use as thrombin inhibitors | |
| NO20016403D0 (en) | Substituted purine derivatives as inhibitors of cell adhesion | |
| DK1214302T3 (en) | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their use as lipase inhibitors | |
| NO20005301D0 (en) | Pyrrolidines as inhibitors of neuraminidases | |
| EE200100084A (en) | New pharmaceutical uses of NOS inhibitors | |
| NO20030820L (en) | Use of vitamin D derivatives as bone resorption inhibitors | |
| NO20006349D0 (en) | Hydroxamic acid derivatives as inhibitors of human CD23 production and TNF release | |
| NO20003199D0 (en) | Benzo (C) quinolizine derivatives and their use as 5- <alpha> reductase inhibitors | |
| DK0920330T3 (en) | hCG and derivatives as inhibitors of matrix metalloproteases |